Market Overview

Top 4 Mid-Cap Stocks In The Drugs-Generic Industry With The Highest ROA

Share:
Related AKRX
Piper Jaffray: Akorn's Stock Will Be Delisted In 2016
Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
Related SLXP
Benzinga's Volume Movers
US Stock Futures Edge Lower Ahead Of ADP Report

Below are the top mid-cap drugs-generic stocks on the NYSE and the NASDAQ in terms of return on assets.

The trailing-twelve-month return on assets at Akorn (NASDAQ: AKRX) is 13.00%. Akorn's EPS for the same period is $0.46.

The trailing-twelve-month return on assets at Salix Pharmaceuticals (NASDAQ: SLXP) is 6.40%. Salix's revenue for the same period is $1.12 billion.

The trailing-twelve-month return on assets at Mallinckrodt plc (NYSE: MNK) is 2.50%. Mallinckrodt's operating margin for the same period is 9.20%.

The trailing-twelve-month return on assets at Hospira (NYSE: HSP) is 1.00%. Hospira's PEG ratio is 5.78.

Posted-In: Drugs-Generic Industry Mid-Cap ROATrading Ideas

 

Related Articles (AKRX + HSP)

Get Benzinga's Newsletters